Vectus Biosystems Limited

As of June 30, 2024, Vectus Biosystems Limited carries a market capitalization of 4.10M, placing it among publicly traded companies globally. Its enterprise value stands at 3.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, Vectus Biosystems Limited has 53.21M shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, Vectus Biosystems Limited maintains a current ratio of 3.45, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.95, indicating elevated leverage, while an interest coverage ratio of -391.69 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2024, Vectus Biosystems Limited posted a negative return on equity (ROE) of -93.34, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -70.26, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Vectus Biosystems Limited's stock has gained approximately 21.62% over the past 52 weeks. The 50-day moving average sits at 0.15, while the 200-day moving average is 0.13.

These figures cover the twelve months ended June 30, 2024. EBITDA reached -3.41M, while operating income came in at -3.47M.

As of June 30, 2024, Vectus Biosystems Limited holds 808,969.00 in cash and equivalents against 28,926.00 in total debt, resulting in a net debt position of -808,969.00. Total book value stands at 1.49M, with working capital of 1.31M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield reaches 1.01, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vectus Biosystems Limited shareholders.